Goldman Sachs has initiated coverage on Avidity Biosciences, a clinical-stage biotech company developing RNA therapeutics for muscular dystrophies, with a Buy rating and a $59 price target. The analyst sees significant commercial potential for Avidity’s lead assets, particularly del-brax for FSHD and del-desiran for DM1, both of which are poised to be first-to-market treatments.